HomeBUSINESS
BUSINESS

Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
(Mar.13.2018)

By Reiji Anasako

Eisai’s mega-scale collaboration deal with US Merck on its cancer drug Lenvima (lenvatinib) could pull the Japanese drug maker out of the post-Aricept (donepezil)/Pariet (rabeprazole) doldrums and help it achieve the ambitious 800 billion yen sales target set for FY2020 ...
(LOG IN FOR FULL STORY)